FDA approves Keryx's Auryxia for non-dialysis-dependent CKD

Keryx Biopharmaceuticals Inc. (NASDAQ:KERX) said FDA approved an sNDA for Auryxia ferric citrate (Fexeric - EU, Riona - Japan, KRX-0502, JTT-751) to treat iron deficiency anemia in patients with non-dialysis-dependent chronic kidney disease (CKD). The oral ferric iron-based phosphate binder is already approved in the U.S. to control serum phosphorous levels in patients with CKD on dialysis...